Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.64 |
| ▸ | MAOA | P21397 | 3/20 | 0.60 |
| ▸ | HRH1 | P35367 | 4/20 | 0.59 |
| ▸ | HTR2A | P28223 | 2/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9043073 | 1.00 | MAOB (0.64) | MAOBMAOAHRH1HTR2AGFER | |
| SCHEMBL6014350 | 1.00 | MAOB (0.64) | MAOBMAOAHRH1HTR2AGFER | |
| SCHEMBL9840873 | 1.00 | MAOB (0.64) | MAOBMAOAHRH1HTR2AGFER | |
| SCHEMBL9840456 | 1.00 | MAOB (0.64) | MAOBMAOAHRH1HTR2AGFER | |
| SCHEMBL2328304 | 0.98 | MAOB (0.67) | MAOBMAOAHRH1HTR2AGFER | |
| SCHEMBL238409 | 0.90 | GFER (0.65) | MAOBMAOAHRH1HTR2AGFER | |
| SCHEMBL20251158 | 0.90 | MAOB (0.76) | MAOBMAOAHRH1HTR2AGFER | |
| SCHEMBL4022346 | 0.90 | MAOB (0.76) | MAOBMAOAHRH1HTR2AGFER | |
| SCHEMBL4021564 | 0.90 | MAOB (0.76) | MAOBMAOAHRH1HTR2AGFER | |
| SCHEMBL9350714 | 0.90 | MAOA (0.71) | MAOBMAOAHRH1HTR2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367166-A1 | NEXT GENERATION DIPROVOCIMS THAT ACTIVATE THE INNATE AND ADAPTIVE IMMUNE RESPONSE | SCRIPPS RESEARCH INST (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2023212650-A1 | NEXT GENERATION DIPROVOCIMS THAT ACTIVATE THE INNATE AND ADAPTIVE IMMUNE RESPONSE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367166-A1 | NEXT GENERATION DIPROVOCIMS THAT ACTIVATE THE INNATE AND ADAPTIVE IMMUNE RESPONSE | TLR1, TLR4, TLR3 | MAOB 4102/4885MAOA 4248/4885HRH1 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.